Quantum BioPharma Ltd. Files Form 6-K Reporting Lawsuit and Business Updates

Quantum BioPharma Ltd. has filed a Form 6-K report detailing a class action lawsuit filed against Canadian banks CIBC and RBC for alleged stock market manipulation of Quantum BioPharma shares. The lawsuit, initiated by shareholder Paul Durkacz, claims significant harm to investors who sold securities between January 6, 2021, and October 15, 2025. Quantum BioPharma intends to seek appointment as lead plaintiff to protect its shareholders. The company also announced the renewal of its services with LWM for one month starting December 22, 2025. Additionally, the report provides an update on Quantum BioPharma's business, including its focus on neurodegenerative and metabolic disorders, its subsidiary Lucid Psycheceuticals Inc. and its lead compound Lucid-MS for multiple sclerosis, and its stake in Unbuzzd Wellness Inc. The company also holds strategic investments through FSD Strategic Investments Inc. The filing includes forward-looking statements regarding litigation, business performance, and potential acquisitions, alongside associated risks and uncertainties.